Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

doi:10.1136/bmj.39554.624086.AD

BMJ 2008;336:1246-1248 (31 May), doi:10.1136/bmj.39554.624086.AD

Practice

Guidelines

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

Angela Cooper, senior health services research fellow, Norma O’Flynn, clinical director , on behalf of the Guideline Development Group

¹ National Collaborating Centre for Primary Care, Royal College of General Practitioners, London SW7 1PU

Correspondence to: N O’Flynn noflynn@rcgp.org.uk

The first 150 words of the full text of this article appear below.

Cardiovascular disease remains a leading cause of morbidityand mortality in the United Kingdom. Randomised controlled trialshave shown benefit from modifying risk factors in people atrisk of developing cardiovascular disease and in those who haveevidence of established disease. Currently patients are oftenassessed opportunistically and treated on the basis of individualclinical or laboratory results rather than on their overalllevel of risk of developing cardiovascular disease. This articlesummarises the most recent recommendations from the NationalInstitute for Health and Clinical Excellence (NICE) on the effectiveidentification and assessment of people at risk of cardiovasculardisease, and on the modification of lipids in primary and secondaryprevention. The detailed consideration of the evidence is availablein the full guideline (www.nice.org.uk/ CG67).¹

NICE recommendations are based on systematic reviews of bestavailable evidence. When minimal evidence is available, recommendationsare based on the guideline development group’s . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to StumbleUpon StumbleUpon Add to Technorati Technorati What's this?

Relevant Articles

An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study: Gary S Collins and Douglas G Altman
BMJ 2009 339: b2584. [Abstract] [Full Text] [PDF]

QRISK or Framingham for predicting cardiovascular risk?: Rod Jackson, Roger Marshall, Andrew Kerr, Tania Riddell, and Sue Wells
BMJ 2009 339: b2673. [Extract] [Full Text]

Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes: Rod Jackson, Sue Wells, and Anthony Rodgers
BMJ 2008 337: a1371. [Extract] [Full Text]

Cardiovascular risk tables: Thierry Christiaens
BMJ 2008 336: 1445-1446. [Extract] [Full Text] [PDF]

NICE has overestimated cardiovascular risk: Richard G Richards
BMJ 2008 336: 1323-1324. [Extract] [Full Text] [PDF]

NICE’s simplified approach to lipids will not work: Stuart J Laurie
BMJ 2008 336: 1324. [Extract] [Full Text] [PDF]

Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease: Francesco P Cappuccio
BMJ 2008 336: 1248-1249. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

Collins, G. S, Altman, D. G (2009). An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 339: b2584-b2584 [Abstract] [Full text]
Jackson, R., Marshall, R., Kerr, A., Riddell, T., Wells, S. (2009). QRISK or Framingham for predicting cardiovascular risk?. BMJ 339: b2673-b2673 [Full text]
Jackson, R., Wells, S., Rodgers, A. (2008). Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes. BMJ 337: a1371-a1371 [Full text]
Hird, M. I (2008). NICE's simplified approach can't not work. BMJ 336: 1454-1454 [Full text]
Christiaens, T. (2008). Cardiovascular risk tables. BMJ 336: 1445-1446 [Full text]
Laurie, S. J (2008). NICE's simplified approach to lipids will not work. BMJ 336: 1324-1324 [Full text]
Richards, R. G (2008). NICE has overestimated cardiovascular risk. BMJ 336: 1323-1324 [Full text]

Rapid Responses:

Read all Rapid Responses

NICE Lipid modification guidance: Stuart J Laurie
bmj.com, 31 May 2008 [Full text]
Sibling cardiovascular disease (CVD) is a stronger risk factor than parental CVD for premature CVD: Mark N Upton
bmj.com, 1 Jun 2008 [Full text]
Elementary epidemiological error.: Richard G Richards
bmj.com, 3 Jun 2008 [Full text]
NICE lipid modification guidance and secondary prevention in ischemic stroke patients: moderate versus intensive statin therapy: Luis Castilla-Guerra, et al.
bmj.com, 4 Jun 2008 [Full text]
Where's mention of low dose, low cost aspirin!: Caroline A Mitchell
bmj.com, 5 Jun 2008 [Full text]
The Department of Health should recommend QRISK: Kambiz Boomla
bmj.com, 5 Jun 2008 [Full text]
NICE recommendations: words of caution.: Mark R Goldstein, MD, et al.
bmj.com, 5 Jun 2008 [Full text]
Message to NICE: statins fail to save women: Eddie Vos
bmj.com, 5 Jun 2008 [Full text]
Has NICE got the wrong end of the prevention stick?: Guy W L Lloyd
bmj.com, 9 Jun 2008 [Full text]
Clinical judgement, ethnicity and cardiovascular risk: Raj S. Bhopal, et al.
bmj.com, 13 Jun 2008 [Full text]
Re: Has NICE got the wrong end of the prevention stick? I think not: L Sam Lewis
bmj.com, 13 Jun 2008 [Full text]
Comment on Non-inclusion of Plant Sterols in the NICE Guidance for Lipid Modification: Peter J. Jones
bmj.com, 1 Sep 2008 [Full text]
The Cost Implications of NICE Guidance for More Aggressive Lipid Lowering Therapy for Troponin Positive Acute Coronary Syndrome Patients: Munish Bhuchar, et al.
bmj.com, 27 Nov 2008 [Full text]